Previously submitted to: JMIR mHealth and uHealth (no longer under consideration since Oct 23, 2018)
Date Submitted: Sep 30, 2018
Open Peer Review Period: Sep 30, 2018 - Oct 9, 2018
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-phone Management System: A Prospective Cohort Study
Background:
Ankylosing spondylitis (AS) is a chronic disease that mainly affects the axial skeleton, leading to decreased mobility, function, and quality of life. With the advent of mobile health (mHealth) technologies, it is now possible to create more economical, sustainable, and user-friendly communication and health monitoring systems to improve the effectiveness of patient care and to gather real-world clinical data for clinical research.
Objective:
To introduce “smart-phone Spondyloarthritis Management System” (SpAMS), an interactive mobile health (mHealth) tool, specifically designed for longitudinal disease management and prospective ankylosing spondylitis (AS)/spondyloarthritis (SpA) and to evaluate the clinical profile of Chinese (AS) patients.
Methods:
SpAMS integrates the patient’s portal and the physician’s portal in a cell phone application. By using SpAMS, Chinese Ankylosing Spondylitis Prospective Imaging Cohort (CASPIC) was launched from April 2016. All patients fulfilled the 1984 modified New York criteria. Patient self-assessments were completed online at baseline and at every subsequent clinic visit. Physician-reported assessments and treatment regimens were recorded by rheumatologists during each visit.
Results:
In total, 1201 AS patients [mean (SD) age, 30.6 (8.7) years; male, 82.6%] were recruited. The mean (SD) disease duration was 8.4 (6.1) years. A history or current symptoms suggestive of acute anterior uveitis (AAU), psoriasis, and inflammatory bowel disease (IBD) were observed in 21.0%, 3.7%, and 9.4% of the patients, respectively. AAU and IBD were found significantly more in patients with a symptom duration > 10 years (31.1%, 12.5%, respectively). At the baseline visit, the most commonly used medications were non-steroidal anti-inflammatory drugs (NSAIDs) (98.2%). Patients using tumor necrosis factor inhibitors (TNFi) accounted for 20.8% of enrolled patients. Additionally, 66.4% of patients used conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs). At baseline, the percentage of patients with inactive disease (ID)/low disease activity (LDA) was 57.2%, and this value improved significantly to 79.2% after a mean follow-up of 13.3 (5.9) months. Compared with relapsed patients, new achievers of ID/LDA underwent more online patient assessments (P < .001). By solving problems in SpAMS, 29.1% of clinic visits were unnecessary and therefore time had been saved. At least an average of 5.3 hours and 327.4 RMB per person spent on traffic was saved through SpAMS. The saved traffic expenses were equal to 16% of the Chinese monthly disposable personal income.
Conclusions:
SpAMS is a time- and cost-saving disease management tool, helping AS patients perform self-management and providing valuable data to clinicians. This is the first nationwide real-world study of AS patients in China who use mHealth technology, and our results contribute significantly to characterizing the clinical profiles of Chinese patients with AS.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.